CytomX Therapeutics Company Profile (NASDAQ:CTMX)

About CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics logoCytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTMX
  • CUSIP: N/A
  • Web:
  • Market Cap: $525.88 million
  • Outstanding Shares: 36,749,000
Average Prices:
  • 50 Day Moving Avg: $15.45
  • 200 Day Moving Avg: $13.41
  • 52 Week Range: $9.10 - $20.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.66
  • P/E Growth: -1.88
Sales & Book Value:
  • Annual Revenue: $24.47 million
  • Price / Sales: 21.49
  • Book Value: $2.01 per share
  • Price / Book: 7.12
  • EBIDTA: ($50,250,000.00)
  • Net Margins: -523.78%
  • Return on Equity: -52.50%
  • Return on Assets: -28.57%
  • Current Ratio: 7.74%
  • Quick Ratio: 7.74%
  • Average Volume: 293,297 shs.
  • Beta: 1.1
  • Short Ratio: 3.89

Frequently Asked Questions for CytomX Therapeutics (NASDAQ:CTMX)

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) issued its earnings results on Friday, May, 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.55) by $0.32. The company had revenue of $11.65 million for the quarter, compared to analysts' expectations of $2.10 million. CytomX Therapeutics had a negative net margin of 523.78% and a negative return on equity of 52.50%. View CytomX Therapeutics' Earnings History.

When will CytomX Therapeutics make its next earnings announcement?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for CytomX Therapeutics.

Where is CytomX Therapeutics' stock going? Where will CytomX Therapeutics' stock price be in 2017?

8 brokers have issued 12-month target prices for CytomX Therapeutics' stock. Their predictions range from $24.00 to $32.00. On average, they anticipate CytomX Therapeutics' stock price to reach $27.00 in the next year. View Analyst Ratings for CytomX Therapeutics.

What are analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:

  • 1. HC Wainwright analysts commented, "Before the market opened on May 5, TG reported 1Q17 results. The company recently reported preliminary data from its ongoing Phase II study of TG-1101 in patients with relapsing forms of multiple sclerosis. Preliminary results indicated that TG-1101 was well tolerated with no Grade III/IV adverse events (AEs) observed and the most commonly reported AE being infusion-related reactions, with median time on study of five months. All patients achieved the primary endpoint of greater than 95% B-cell depletion by four weeks. The median B-cell depletion at week four was reported to be 99% after two infusions with a cumulative dose of 600 mg, which compares favorably to other anti-CD20 monoclonal antibodies (mAbs). Management indicated that additional data from the ongoing Phase II study will be reported later this year and that the company is on track to initiate a Phase III trial in MS in 2H17." (5/8/2017)
  • 2. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (5/3/2017)
  • 3. Cann analysts commented, "CytomX today announced the appointment of Marion McCourt to the board of directors. Ms." (3/30/2017)
  • 4. Instinet analysts commented, "We are initiating on CytomX Therapeutics (CTMX) with a Buy rating and $21 12-month target price. We recommend owning CTMX shares ahead of 2H17 and 2018 data readouts for CX-072 and CX-2009, which we anticipate will validate the platforms MOA and frame breadth of utility. We remain focused on CX-072 in combo with Zelboraf, on the belief that a strong signal here will provide clear proof-of-concept for the approach, thus limiting downside risk. We look to CX-2009 as an opportunity for potentially significant upside given the high unmet need of solid tumors that express CD166. The potential for value to be ascribed to CTMX pipeline candidates presents upside potential to our estimates." (3/1/2017)
  • 5. Cowen and Company analysts commented, "CTMX announced this morning that the first patient has been dosed in CX-072’s." (2/2/2017)

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a drop in short interest during the month of April. As of April 13th, there was short interest totalling 714,953 shares, a drop of 8.4% from the March 31st total of 780,500 shares. Based on an average daily trading volume, of 209,145 shares, the short-interest ratio is currently 3.4 days.

Who are some of CytomX Therapeutics' key competitors?

Who owns CytomX Therapeutics stock?

CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Perceptive Advisors LLC (4.17%), Vanguard Group Inc. (2.26%), EcoR1 Capital LLC (2.16%), Redmile Group LLC (1.86%) and Tekla Capital Management LLC (1.45%). Company insiders that own CytomX Therapeutics stock include Cynthia J Ladd, Frederick W Gluck, Ix LP Canaan, James E Flynn, Kevin P Starr, Robert C Goeltz II, Rock Ventures Lp Third, Sean A Mccarthy and Timothy M Shannon. View Institutional Ownership Trends for CytomX Therapeutics.

Who sold CytomX Therapeutics stock? Who is selling CytomX Therapeutics stock?

CytomX Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Tekla Capital Management LLC, Bank of America Corp DE, Private Advisor Group LLC, Redmile Group LLC, Morgan Stanley, TIAA CREF Investment Management LLC and Nationwide Fund Advisors. Company insiders that have sold CytomX Therapeutics stock in the last year include Ix LP Canaan, Kevin P Starr, Robert C Goeltz II, Rock Ventures Lp Third, Sean A Mccarthy and Timothy M Shannon. View Insider Buying and Selling for CytomX Therapeutics.

Who bought CytomX Therapeutics stock? Who is buying CytomX Therapeutics stock?

CytomX Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Perceptive Advisors LLC, Driehaus Capital Management LLC, JPMorgan Chase & Co., Sphera Funds Management LTD., Renaissance Technologies LLC, Iguana Healthcare Management LLC and Monashee Investment Management LLC. Company insiders that have bought CytomX Therapeutics stock in the last two years include Cynthia J Ladd, Frederick W Gluck and James E Flynn. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy CytomX Therapeutics stock?

Shares of CytomX Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CytomX Therapeutics stock cost?

One share of CytomX Therapeutics stock can currently be purchased for approximately $14.31.

Analyst Ratings

Consensus Ratings for CytomX Therapeutics (NASDAQ:CTMX) (?)
Ratings Breakdown: 2 Sell Ratings, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $27.00 (88.68% upside)

Analysts' Ratings History for CytomX Therapeutics (NASDAQ:CTMX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017ValuEngineDowngradeHold -> SellLowView Rating Details
5/8/2017HC WainwrightReiterated RatingBuyLowView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingBuy$25.00LowView Rating Details
3/30/2017CannReiterated RatingHoldLowView Rating Details
3/20/2017InstinetBoost Price TargetSell$21.00 -> $32.00MediumView Rating Details
3/4/2017Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
2/2/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/2/2015Bank of America CorpInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for CytomX Therapeutics (NASDAQ:CTMX)
Earnings by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Earnings History by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1 2017($0.55)($0.23)$2.10 million$11.65 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.45)($0.39)$6.27 millionViewN/AView Earnings Details
11/3/2016Q3($0.35)($0.40)$3.20 million$3.45 millionViewN/AView Earnings Details
8/3/2016Q2($0.41)($0.39)$2.10 million$3.09 millionViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.44)$6.00 million$2.22 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CytomX Therapeutics (NASDAQ:CTMX)
2017 EPS Consensus Estimate: ($2.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.48)($0.48)($0.48)
Q2 20172($1.04)($0.53)($0.79)
Q3 20172($1.05)($0.55)($0.80)
Q4 20172($0.96)($0.57)($0.77)
(Data provided by Zacks Investment Research)


Dividend History for CytomX Therapeutics (NASDAQ:CTMX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CytomX Therapeutics (NASDAQ:CTMX)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 54.31%
Insider Trades by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Insider Trades by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Sean A MccarthyInsiderSell4,781$15.70$75,061.70View SEC Filing  
4/12/2017Kevin P StarrMajor ShareholderSell28,357$16.36$463,920.52View SEC Filing  
4/4/2017Sean A MccarthyInsiderSell9,562$17.22$164,657.64View SEC Filing  
3/27/2017Rock Ventures Lp ThirdMajor ShareholderSell1,650,000$17.39$28,693,500.00View SEC Filing  
3/20/2017Robert C Goeltz IICFOSell21,517$19.81$426,251.77View SEC Filing  
3/20/2017Sean A MccarthyInsiderSell14,343$19.60$281,122.80View SEC Filing  
3/3/2017Sean A MccarthyInsiderSell14,343$15.00$215,145.00View SEC Filing  
11/28/2016Ix L.P. CanaanDirectorSell38,459$11.56$444,586.04View SEC Filing  
11/22/2016Ix L.P. CanaanDirectorSell42,550$11.71$498,260.50View SEC Filing  
11/21/2016Ix L.P. CanaanDirectorSell45,324$11.61$526,211.64View SEC Filing  
11/16/2016Ix L.P. CanaanDirectorSell51,581$11.50$593,181.50View SEC Filing  
11/15/2016Timothy M ShannonDirectorSell33,064$11.48$379,574.72View SEC Filing  
11/14/2016Ix L.P. CanaanDirectorSell86,270$11.16$962,773.20View SEC Filing  
11/9/2016Ix L.P. CanaanDirectorSell13,730$11.03$151,441.90View SEC Filing  
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89View SEC Filing  
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62View SEC Filing  
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.00View SEC Filing  
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00View SEC Filing  
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CytomX Therapeutics (NASDAQ:CTMX)
Latest Headlines for CytomX Therapeutics (NASDAQ:CTMX)
DateHeadline logoZacks: Brokerages Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.37 Per Share - May 27 at 12:30 AM logoCytomX to Present at the Jefferies 2017 Global Healthcare Conference - May 25 at 6:14 PM logoETFs with exposure to CytomX Therapeutics, Inc. : May 22, 2017 - May 22 at 4:22 PM logoCytomX Therapeutics Inc (CTMX) Given Consensus Rating of "Hold" by Brokerages - May 22 at 4:04 PM logoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 4:26 PM logoCytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting - May 17 at 11:24 AM logoShould CytomX Therapeutics (CTMX) Be On Your Radar Now? - May 16 at 12:10 PM logoCytomX Announces Management Team Changes - May 15 at 4:27 PM logoCytomX Therapeutics Inc (CTMX) Lowered to "Sell" at ValuEngine - May 13 at 3:22 PM logoCytomX Therapeutics Inc (CTMX) Given "Buy" Rating at HC Wainwright - May 8 at 9:36 PM logoCytomX Therapeutics Inc (CTMX) Announces Quarterly Earnings Results, Beats Expectations By $0.32 EPS - May 8 at 3:18 PM logoCytomX Announces First Quarter 2017 Financial Results - May 5 at 4:48 PM logoCytomX Therapeutics reports 1Q loss - May 5 at 4:48 PM logoZacks: Brokerages Expect CytomX Therapeutics Inc (CTMX) Will Announce Quarterly Sales of $2.1 Million - May 5 at 3:14 PM logoCytomX Therapeutics, Inc. – Value Analysis (NASDAQ:CTMX) : May 4, 2017 - May 4 at 9:43 PM logoCytomX Therapeutics Inc (CTMX) Sees Large Decrease in Short Interest - May 4 at 1:01 AM logoCytomX Therapeutics Inc (CTMX) Lifted to Buy at Zacks Investment Research - May 4 at 12:58 AM logo Analysts Expect CytomX Therapeutics Inc (CTMX) Will Announce Earnings of -$0.55 Per Share - May 3 at 2:08 PM logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : May 3, 2017 - May 3 at 9:08 AM logoCytomX Therapeutics Inc (CTMX) Set to Announce Quarterly Earnings on Friday - May 3 at 8:08 AM logoSean A. Mccarthy Sells 4,781 Shares of CytomX Therapeutics Inc (CTMX) Stock - May 2 at 10:22 PM logoCytomX Therapeutics (CTMX) Receives Coverage Optimism Score of 0.22 - May 2 at 12:54 PM logoCytomX Therapeutics (CTMX) Getting Somewhat Favorable News Coverage, Report Finds - April 29 at 2:51 PM logoCytomX Therapeutics to Announce First Quarter 2017 Financial Results - April 27 at 5:05 PM logoCytomX Therapeutics Inc (CTMX) Given Average Rating of "Hold" by Brokerages - April 25 at 4:24 PM logoCytomX Therapeutics (CTMX) Earning Somewhat Favorable News Coverage, Study Shows - April 23 at 5:07 PM logoCytomX Therapeutics (CTMX) Receiving Positive Media Coverage, Study Shows - April 20 at 4:53 PM logoCytomX Therapeutics' (CTMX) Hold Rating Reiterated at Cann - April 16 at 1:28 PM logoCytomX Therapeutics (CTMX) Given Daily News Impact Score of 0.54 - April 15 at 9:07 AM logoKevin P. Starr Sells 28,357 Shares of CytomX Therapeutics Inc (CTMX) Stock - April 14 at 4:57 PM logoCytomX Therapeutics Inc (CTMX) Expected to Post Quarterly Sales of $2.1 Million - April 14 at 2:16 PM logo-$0.55 EPS Expected for CytomX Therapeutics Inc (CTMX) This Quarter - April 12 at 9:15 AM logoETFs with exposure to CytomX Therapeutics, Inc. : April 7, 2017 - April 7 at 4:32 PM logoETFs with exposure to CytomX Therapeutics, Inc. : April 7, 2017 - April 7 at 4:32 PM logoCytomX Therapeutics Inc (CTMX) Insider Sells $164,657.64 in Stock - April 5 at 3:25 PM logoCytomX Therapeutics Appoints Marion McCourt to Board of Directors - March 30 at 4:58 PM logoCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh - March 30 at 4:58 PM logoCoverage initiated on CytomX Therapeutics by H.C. Wainwright - March 28 at 12:24 PM logoCytomX Therapeutics Inc (CTMX) Major Shareholder Rock Ventures Lp Third Sells 1,650,000 Shares - March 27 at 10:25 PM logoCytomX Therapeutics Inc (CTMX) Now Covered by HC Wainwright - March 27 at 9:35 AM logoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 - March 21 at 9:51 PM logoInsider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 21,517 Shares of Stock - March 21 at 7:39 PM logoInsider Selling: CytomX Therapeutics Inc (CTMX) Insider Sells 14,343 Shares of Stock - March 21 at 7:37 PM logoCytomX Therapeutics Inc. (CTMX) Jumped To A New High On Bristol-Myers Deal - March 21 at 10:16 AM logoStocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News - March 21 at 10:16 AM logoCytomX Therapeutics (CTMX) Has Jumped To A 10-Month High On Bristol-Myers Deal - March 20 at 5:55 PM logoInstinet Increases CytomX Therapeutics Inc (CTMX) Price Target to $32.00 - March 20 at 1:09 PM logoCYTOMX THERAPEUTICS, INC. Financials - March 8 at 5:18 PM logoCytomX Therapeutics Inc (CTMX) Research Coverage Started at Instinet - March 8 at 7:51 AM logoCYTOMX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report - March 2 at 9:52 PM



CytomX Therapeutics (CTMX) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff